Global Kidney Renal Cancer Drugs Market

Kidney Renal Cancer Drugs Comprehensive Study by Type (Anti-angiogenesis therapy, Tyrosine kinase inhibitors (TKIs), MTOR inhibitors), Application (Clear cell renal cell carcinomas (ccRCC), Papillary renal cell carcinoma (PRCC), Chromophobe RCC, Collecting duct RCC, Unclassified RCC, Others), End-User (Hospitals, Cancer Therapy Centers, Home Care Settings) Players and Region - Global Market Outlook to 2030

Kidney Renal Cancer Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Kidney Renal Cancer Drugs
Renal cell carcinoma, a form of kidney cancer that involves cancerous changes in the cells of the renal tubule, is the most common type of kidney cancer in adults. Chemotherapy (chemo) is a treatment that involves the administration of anti-cancer medications through a vein (IV) or by mouth (as pills). Because these treatments penetrate the bloodstream and reach practically every part of the body, they may be useful for cancer that has spread (metastasized) to organs other than the kidney. The medicines target parts of cancer cells that help them grow and survive. They're designed to kill cancer without harming healthy cells. This year, it is expected that 73,820 people will be diagnosed with kidney cancer, with 14,770 dying from the condition. Although metastatic renal cell cancer (RCC) has a 5-year survival rate of only 12%, a number of recently authorised treatments are improving results for those with advanced renal cell carcinoma.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Kidney Renal Cancer Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Active Biotech AB (Sweden), Amgen (United States), Bayer AG (Germany), Cipla Limited (India), F. Hoffmann-La Roche AG (Switzerland), Genentech, Inc. (United States), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Onyx Pharmaceuticals Inc. (United States) and Pfizer, Inc. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Kidney Renal Cancer Drugs market by Type (Anti-angiogenesis therapy, Tyrosine kinase inhibitors (TKIs) and mTOR inhibitors), Application (Clear cell renal cell carcinomas (ccRCC), Papillary renal cell carcinoma (PRCC), Chromophobe RCC, Collecting duct RCC, Unclassified RCC and Others) and Region.



On the basis of geography, the market of Kidney Renal Cancer Drugs has been segmented into South America (Brazil, Argentina, Chile, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Singapore, Indonesia, Thailand, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Spain, Sweden, Belgium, Finland, Denmark, Russia, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-User, the sub-segment i.e. Hospitals will boost the Kidney Renal Cancer Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Expenditure on Healthcare

Market Growth Drivers:
Increasing Incidence of the Disease and Rising Geriatric Population and Surge in Kidney Cancer Screening

Challenges:
Side effects of Drugs

Opportunities:
Improvement in Diagnostic Technologies and Larger Number of Patients under Treatment and Better Treatment Prospects Compared to Traditional Therapies

Market Leaders and their expansionary development strategies
In June 2020, Oncology Venture A/S acquired the remaining 37% ownership stake in its experimental cancer therapy dovitinib from investor Sass & Larsen Aps.
In February 2021, Glenmark Pharma launched a generic kidney cancer treatment drug 'Sunitinib oral capsules' in India priced 96 per cent lower compared to the innovator brand.
FDA published guidance on October 1, 2020 regarding the development of drugs and biologics for the adjuvant treatment of renal cell carcinoma. Eligibility criteria, choice of comparator, follow-up imaging assessments, determination of disease recurrence, analyses of disease-free survival (DFS), and interpretation of trial results are discussed in the guidance document. According to FDA, the guidance is focused on clinical trials with DFS as the primary efficacy endpoint.

Key Target Audience
Pharmaceutical Manufacturers, Suppliers of Pharmaceutical, Wholesalers, Distributors and Retailers of Pharmaceutical, Healthcare Industry, Regulatory & Government Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Anti-angiogenesis therapy
  • Tyrosine kinase inhibitors (TKIs)
  • mTOR inhibitors
By Application
  • Clear cell renal cell carcinomas (ccRCC)
  • Papillary renal cell carcinoma (PRCC)
  • Chromophobe RCC
  • Collecting duct RCC
  • Unclassified RCC
  • Others
By End-User
  • Hospitals
  • Cancer Therapy Centers
  • Home Care Settings

By Regions
  • South America
    • Brazil
    • Argentina
    • Chile
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Indonesia
    • Thailand
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Spain
    • Sweden
    • Belgium
    • Finland
    • Denmark
    • Russia
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence of the Disease and Rising Geriatric Population
      • 3.2.2. Surge in Kidney Cancer Screening
    • 3.3. Market Challenges
      • 3.3.1. Side effects of Drugs
    • 3.4. Market Trends
      • 3.4.1. Increasing Expenditure on Healthcare
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Kidney Renal Cancer Drugs, by Type, Application, End-User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Kidney Renal Cancer Drugs (Value)
      • 5.2.1. Global Kidney Renal Cancer Drugs by: Type (Value)
        • 5.2.1.1. Anti-angiogenesis therapy
        • 5.2.1.2. Tyrosine kinase inhibitors (TKIs)
        • 5.2.1.3. MTOR inhibitors
      • 5.2.2. Global Kidney Renal Cancer Drugs by: Application (Value)
        • 5.2.2.1. Clear cell renal cell carcinomas (ccRCC)
        • 5.2.2.2. Papillary renal cell carcinoma (PRCC)
        • 5.2.2.3. Chromophobe RCC
        • 5.2.2.4. Collecting duct RCC
        • 5.2.2.5. Unclassified RCC
        • 5.2.2.6. Others
      • 5.2.3. Global Kidney Renal Cancer Drugs by: End-User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Cancer Therapy Centers
        • 5.2.3.3. Home Care Settings
      • 5.2.4. Global Kidney Renal Cancer Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Chile
          • 5.2.4.1.4. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Singapore
          • 5.2.4.2.6. Indonesia
          • 5.2.4.2.7. Thailand
          • 5.2.4.2.8. Australia
          • 5.2.4.2.9. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Spain
          • 5.2.4.3.7. Sweden
          • 5.2.4.3.8. Belgium
          • 5.2.4.3.9. Finland
          • 5.2.4.3.10. Denmark
          • 5.2.4.3.11. Russia
          • 5.2.4.3.12. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Kidney Renal Cancer Drugs (Price)
      • 5.3.1. Global Kidney Renal Cancer Drugs by: Type (Price)
  • 6. Kidney Renal Cancer Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Active Biotech AB (Sweden)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Amgen (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cipla Limited (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Genentech, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline plc (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Onyx Pharmaceuticals Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Kidney Renal Cancer Drugs Sale, by Type, Application, End-User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Kidney Renal Cancer Drugs (Value)
      • 7.2.1. Global Kidney Renal Cancer Drugs by: Type (Value)
        • 7.2.1.1. Anti-angiogenesis therapy
        • 7.2.1.2. Tyrosine kinase inhibitors (TKIs)
        • 7.2.1.3. MTOR inhibitors
      • 7.2.2. Global Kidney Renal Cancer Drugs by: Application (Value)
        • 7.2.2.1. Clear cell renal cell carcinomas (ccRCC)
        • 7.2.2.2. Papillary renal cell carcinoma (PRCC)
        • 7.2.2.3. Chromophobe RCC
        • 7.2.2.4. Collecting duct RCC
        • 7.2.2.5. Unclassified RCC
        • 7.2.2.6. Others
      • 7.2.3. Global Kidney Renal Cancer Drugs by: End-User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Cancer Therapy Centers
        • 7.2.3.3. Home Care Settings
      • 7.2.4. Global Kidney Renal Cancer Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Chile
          • 7.2.4.1.4. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Singapore
          • 7.2.4.2.6. Indonesia
          • 7.2.4.2.7. Thailand
          • 7.2.4.2.8. Australia
          • 7.2.4.2.9. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Spain
          • 7.2.4.3.7. Sweden
          • 7.2.4.3.8. Belgium
          • 7.2.4.3.9. Finland
          • 7.2.4.3.10. Denmark
          • 7.2.4.3.11. Russia
          • 7.2.4.3.12. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Kidney Renal Cancer Drugs (Price)
      • 7.3.1. Global Kidney Renal Cancer Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Kidney Renal Cancer Drugs: by Type(USD Million)
  • Table 2. Kidney Renal Cancer Drugs Anti-angiogenesis therapy , by Region USD Million (2018-2023)
  • Table 3. Kidney Renal Cancer Drugs Tyrosine kinase inhibitors (TKIs) , by Region USD Million (2018-2023)
  • Table 4. Kidney Renal Cancer Drugs MTOR inhibitors , by Region USD Million (2018-2023)
  • Table 5. Kidney Renal Cancer Drugs: by Application(USD Million)
  • Table 6. Kidney Renal Cancer Drugs Clear cell renal cell carcinomas (ccRCC) , by Region USD Million (2018-2023)
  • Table 7. Kidney Renal Cancer Drugs Papillary renal cell carcinoma (PRCC) , by Region USD Million (2018-2023)
  • Table 8. Kidney Renal Cancer Drugs Chromophobe RCC , by Region USD Million (2018-2023)
  • Table 9. Kidney Renal Cancer Drugs Collecting duct RCC , by Region USD Million (2018-2023)
  • Table 10. Kidney Renal Cancer Drugs Unclassified RCC , by Region USD Million (2018-2023)
  • Table 11. Kidney Renal Cancer Drugs Others , by Region USD Million (2018-2023)
  • Table 12. Kidney Renal Cancer Drugs: by End-User(USD Million)
  • Table 13. Kidney Renal Cancer Drugs Hospitals , by Region USD Million (2018-2023)
  • Table 14. Kidney Renal Cancer Drugs Cancer Therapy Centers , by Region USD Million (2018-2023)
  • Table 15. Kidney Renal Cancer Drugs Home Care Settings , by Region USD Million (2018-2023)
  • Table 16. South America Kidney Renal Cancer Drugs, by Country USD Million (2018-2023)
  • Table 17. South America Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 18. South America Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 19. South America Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 20. Brazil Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 21. Brazil Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 22. Brazil Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 23. Argentina Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 24. Argentina Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 25. Argentina Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 26. Chile Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 27. Chile Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 28. Chile Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 29. Rest of South America Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 30. Rest of South America Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 31. Rest of South America Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 32. Asia Pacific Kidney Renal Cancer Drugs, by Country USD Million (2018-2023)
  • Table 33. Asia Pacific Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 34. Asia Pacific Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 35. Asia Pacific Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 36. China Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 37. China Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 38. China Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 39. Japan Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 40. Japan Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 41. Japan Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 42. India Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 43. India Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 44. India Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 45. South Korea Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 46. South Korea Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 47. South Korea Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 48. Singapore Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 49. Singapore Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 50. Singapore Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 51. Indonesia Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 52. Indonesia Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 53. Indonesia Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 54. Thailand Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 55. Thailand Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 56. Thailand Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 57. Australia Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 58. Australia Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 59. Australia Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 60. Rest of Asia-Pacific Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 63. Europe Kidney Renal Cancer Drugs, by Country USD Million (2018-2023)
  • Table 64. Europe Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 65. Europe Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 66. Europe Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 67. Germany Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 68. Germany Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 69. Germany Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 70. France Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 71. France Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 72. France Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 73. Italy Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 74. Italy Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 75. Italy Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 76. United Kingdom Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 77. United Kingdom Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 78. United Kingdom Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 79. Netherlands Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 80. Netherlands Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 81. Netherlands Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 82. Spain Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 83. Spain Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 84. Spain Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 85. Sweden Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 86. Sweden Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 87. Sweden Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 88. Belgium Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 89. Belgium Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 90. Belgium Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 91. Finland Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 92. Finland Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 93. Finland Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 94. Denmark Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 95. Denmark Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 96. Denmark Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 97. Russia Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 98. Russia Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 99. Russia Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 100. Rest of Europe Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 101. Rest of Europe Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 102. Rest of Europe Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 103. MEA Kidney Renal Cancer Drugs, by Country USD Million (2018-2023)
  • Table 104. MEA Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 105. MEA Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 106. MEA Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 107. Middle East Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 108. Middle East Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 109. Middle East Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 110. Africa Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 111. Africa Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 112. Africa Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 113. North America Kidney Renal Cancer Drugs, by Country USD Million (2018-2023)
  • Table 114. North America Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 115. North America Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 116. North America Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 117. United States Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 118. United States Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 119. United States Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 120. Canada Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 121. Canada Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 122. Canada Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 123. Mexico Kidney Renal Cancer Drugs, by Type USD Million (2018-2023)
  • Table 124. Mexico Kidney Renal Cancer Drugs, by Application USD Million (2018-2023)
  • Table 125. Mexico Kidney Renal Cancer Drugs, by End-User USD Million (2018-2023)
  • Table 126. Kidney Renal Cancer Drugs: by Type(USD/Units)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Kidney Renal Cancer Drugs: by Type(USD Million)
  • Table 138. Kidney Renal Cancer Drugs Anti-angiogenesis therapy , by Region USD Million (2025-2030)
  • Table 139. Kidney Renal Cancer Drugs Tyrosine kinase inhibitors (TKIs) , by Region USD Million (2025-2030)
  • Table 140. Kidney Renal Cancer Drugs MTOR inhibitors , by Region USD Million (2025-2030)
  • Table 141. Kidney Renal Cancer Drugs: by Application(USD Million)
  • Table 142. Kidney Renal Cancer Drugs Clear cell renal cell carcinomas (ccRCC) , by Region USD Million (2025-2030)
  • Table 143. Kidney Renal Cancer Drugs Papillary renal cell carcinoma (PRCC) , by Region USD Million (2025-2030)
  • Table 144. Kidney Renal Cancer Drugs Chromophobe RCC , by Region USD Million (2025-2030)
  • Table 145. Kidney Renal Cancer Drugs Collecting duct RCC , by Region USD Million (2025-2030)
  • Table 146. Kidney Renal Cancer Drugs Unclassified RCC , by Region USD Million (2025-2030)
  • Table 147. Kidney Renal Cancer Drugs Others , by Region USD Million (2025-2030)
  • Table 148. Kidney Renal Cancer Drugs: by End-User(USD Million)
  • Table 149. Kidney Renal Cancer Drugs Hospitals , by Region USD Million (2025-2030)
  • Table 150. Kidney Renal Cancer Drugs Cancer Therapy Centers , by Region USD Million (2025-2030)
  • Table 151. Kidney Renal Cancer Drugs Home Care Settings , by Region USD Million (2025-2030)
  • Table 152. South America Kidney Renal Cancer Drugs, by Country USD Million (2025-2030)
  • Table 153. South America Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 154. South America Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 155. South America Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 156. Brazil Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 157. Brazil Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 158. Brazil Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 159. Argentina Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 160. Argentina Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 161. Argentina Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 162. Chile Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 163. Chile Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 164. Chile Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 165. Rest of South America Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 166. Rest of South America Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 167. Rest of South America Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 168. Asia Pacific Kidney Renal Cancer Drugs, by Country USD Million (2025-2030)
  • Table 169. Asia Pacific Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 170. Asia Pacific Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 171. Asia Pacific Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 172. China Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 173. China Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 174. China Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 175. Japan Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 176. Japan Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 177. Japan Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 178. India Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 179. India Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 180. India Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 181. South Korea Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 182. South Korea Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 183. South Korea Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 184. Singapore Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 185. Singapore Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 186. Singapore Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 187. Indonesia Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 188. Indonesia Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 189. Indonesia Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 190. Thailand Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 191. Thailand Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 192. Thailand Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 193. Australia Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 194. Australia Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 195. Australia Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 196. Rest of Asia-Pacific Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 197. Rest of Asia-Pacific Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 198. Rest of Asia-Pacific Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 199. Europe Kidney Renal Cancer Drugs, by Country USD Million (2025-2030)
  • Table 200. Europe Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 201. Europe Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 202. Europe Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 203. Germany Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 204. Germany Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 205. Germany Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 206. France Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 207. France Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 208. France Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 209. Italy Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 210. Italy Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 211. Italy Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 212. United Kingdom Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 213. United Kingdom Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 214. United Kingdom Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 215. Netherlands Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 216. Netherlands Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 217. Netherlands Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 218. Spain Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 219. Spain Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 220. Spain Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 221. Sweden Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 222. Sweden Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 223. Sweden Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 224. Belgium Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 225. Belgium Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 226. Belgium Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 227. Finland Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 228. Finland Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 229. Finland Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 230. Denmark Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 231. Denmark Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 232. Denmark Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 233. Russia Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 234. Russia Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 235. Russia Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 236. Rest of Europe Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 237. Rest of Europe Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 238. Rest of Europe Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 239. MEA Kidney Renal Cancer Drugs, by Country USD Million (2025-2030)
  • Table 240. MEA Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 241. MEA Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 242. MEA Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 243. Middle East Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 244. Middle East Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 245. Middle East Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 246. Africa Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 247. Africa Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 248. Africa Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 249. North America Kidney Renal Cancer Drugs, by Country USD Million (2025-2030)
  • Table 250. North America Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 251. North America Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 252. North America Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 253. United States Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 254. United States Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 255. United States Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 256. Canada Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 257. Canada Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 258. Canada Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 259. Mexico Kidney Renal Cancer Drugs, by Type USD Million (2025-2030)
  • Table 260. Mexico Kidney Renal Cancer Drugs, by Application USD Million (2025-2030)
  • Table 261. Mexico Kidney Renal Cancer Drugs, by End-User USD Million (2025-2030)
  • Table 262. Kidney Renal Cancer Drugs: by Type(USD/Units)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Kidney Renal Cancer Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Kidney Renal Cancer Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Kidney Renal Cancer Drugs: by End-User USD Million (2018-2023)
  • Figure 7. South America Kidney Renal Cancer Drugs Share (%), by Country
  • Figure 8. Asia Pacific Kidney Renal Cancer Drugs Share (%), by Country
  • Figure 9. Europe Kidney Renal Cancer Drugs Share (%), by Country
  • Figure 10. MEA Kidney Renal Cancer Drugs Share (%), by Country
  • Figure 11. North America Kidney Renal Cancer Drugs Share (%), by Country
  • Figure 12. Global Kidney Renal Cancer Drugs: by Type USD/Units (2018-2023)
  • Figure 13. Global Kidney Renal Cancer Drugs share by Players 2023 (%)
  • Figure 14. Global Kidney Renal Cancer Drugs share by Players (Top 3) 2023(%)
  • Figure 15. Global Kidney Renal Cancer Drugs share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Active Biotech AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 18. Active Biotech AB (Sweden) Revenue: by Geography 2023
  • Figure 19. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 20. Amgen (United States) Revenue: by Geography 2023
  • Figure 21. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 23. Cipla Limited (India) Revenue, Net Income and Gross profit
  • Figure 24. Cipla Limited (India) Revenue: by Geography 2023
  • Figure 25. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2023
  • Figure 27. Genentech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Genentech, Inc. (United States) Revenue: by Geography 2023
  • Figure 29. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 31. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 33. Onyx Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Onyx Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Global Kidney Renal Cancer Drugs: by Type USD Million (2025-2030)
  • Figure 38. Global Kidney Renal Cancer Drugs: by Application USD Million (2025-2030)
  • Figure 39. Global Kidney Renal Cancer Drugs: by End-User USD Million (2025-2030)
  • Figure 40. South America Kidney Renal Cancer Drugs Share (%), by Country
  • Figure 41. Asia Pacific Kidney Renal Cancer Drugs Share (%), by Country
  • Figure 42. Europe Kidney Renal Cancer Drugs Share (%), by Country
  • Figure 43. MEA Kidney Renal Cancer Drugs Share (%), by Country
  • Figure 44. North America Kidney Renal Cancer Drugs Share (%), by Country
  • Figure 45. Global Kidney Renal Cancer Drugs: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Active Biotech AB (Sweden)
  • Amgen (United States)
  • Bayer AG (Germany)
  • Cipla Limited (India)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Genentech, Inc. (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Novartis AG (Switzerland)
  • Onyx Pharmaceuticals Inc. (United States)
  • Pfizer, Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 239 Pages 53 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Kidney Renal Cancer Drugs Market Quantitative research analysis
Global Kidney Renal Cancer Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Active Biotech AB (Sweden), Amgen (United States), Bayer AG (Germany), Cipla Limited (India), F. Hoffmann-La Roche AG (Switzerland), Genentech, Inc. (United States), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Onyx Pharmaceuticals Inc. (United States) and Pfizer, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Expenditure on Healthcare" is seen as one of major influencing trends for Kidney Renal Cancer Drugs Market during projected period 2023-2030.
The Kidney Renal Cancer Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Kidney Renal Cancer Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Medical Suppositories Comprehensive Study by Type (Rectal Suppositories, Vaginal Suppositories, Urethral Suppositories), Application (Pediatrics, Geriatrics, Gynaecology), End Users (Hospitals, Clini...
$ 3450
Pharmaceutical Contract Sales Outsourcing Comprehensive Study by Type (Pharmaceutical Equipment’s, Finished Drugs), Services (Clinical Trials, Biomedical Research), End Users (Healthcare Organization...
$ 3450
Specialty Generic Drug Comprehensive Study by Type (Oral, Parenteral, Topical, Injectable, Others.), Application (Cancer, Rheumatoid Arthritis, Hemophilia, H.I.V. Psoriasis, Inflammatory Bowel Diseas...
$ 3450
Codeine Drug Comprehensive Study by Type (Tablets, Syrup), Sales Channels (Direct Sales, In-Direct Sales), End Users (Hospitals, Clinics), Treatment (Pain, Cough, Diarrhea, Others), Form (Tablets, Sy...
$ 3500
HER2 Targeted Therapy Comprehensive Study by Therapy (Immunotherapy, Neoadjuvant Therapy), End Users (Hospitals, Clinics), Treatment (Herceptin, Perjeta, Neratinib, Trastuzumab, Others), Distribution...
$ 3650
Digoxin Testing Comprehensive Study by Type (Elisa Test Kits, Reagents, Instruments), Sales Channels (Direct, Indirect), End Users (Hospital, Specialized Clinics, Diagnostic Centres), Treatment (Hear...
$ 3350